Digital Content

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. We’ll assume you’re ok with this, but you can opt out if you wish. See our 

Footer

Column Name Goes Here

Footer V2

2024 Event

Event Global

New HLTH Insights Programs

Become a Hosted Buyer

Become a Sponsor/Exhibitor

Apply for Media Pass

Promote Your Presence

2023 Event

Event Global Footer

Startup Opportunities

Hotel

2022 Event

LLC Global

2021 Event

LLC Menu Official

LLC Menu

Partnerships + Prevention = Value-Driven Care — featuring Katie Adamson of YMCA

S1 Ep3: Partnerships + Prevention = Value-Driven Care — featuring Katie Adamson of YMCA of the USA

Vice President, Health Partnerships and Policy

Access to Information Equals Freedom of Choice—featuring Silvia Taylor

Having a choice is empowering when you have trustworthy information before. In this episode of the HLTH Matters Podcast, Silvia Taylor, executive vice president and chief communications officer for Novavax, talks about making scientific information accessible to people, especially around the COVID-19 vaccines. Novavax developed a safe COVID-19 vaccine during the pandemic and ensures people have the information they need to make an informed choice about their vaccination worldwide. Silvia shares her insights on the relationships and partnerships Novavax has to deliver that necessary information to points of care in the ever-evolving healthcare market. She also encourages listeners to get informed, talk to their providers, and vaccinate against COVID-19. Learn more about Novavax and Silvia’s work to make scientific health information accessible to people with this episode!  About Silvia Taylor:Silvia Taylor is executive vice president, chief communications officer for Novavax. Ms. Taylor has responsibility for investor relations; public relations; external and internal communications; corporate social responsibility and ESG (environmental, social, and governance) strategy; digital and social media; and meetings, events, and corporate merchandising for the company. She brings more than 25 years of communications and commercial leadership to Novavax. Most recently, she was vice president of global corporate affairs and communications at Autolus Therapeutics plc, where sheled all financial, scientific, and corporate communications. Prior to Autolus, Ms. Taylor was senior vice president of global investor relations and corporate affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of AstraZeneca, including head of marketing, responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as at Pfizer, where she served in key brand and consumer marketing roles. Ms. Taylor earned a Master of Business Administration degree from Columbia University and a Bachelor of Arts degree in foreign affairs from University of Virginia. In 2022, she was elected to the Page Society, a membership organization of chief communications officers of global Fortune-ranked corporations. Things You’ll Learn:<ul><li>People aren’t scientists, but they consume science all day long. </li><li>Novavax is a biotechnology company that makes vaccines and has a platform for adjuvanted protein-based vaccines.</li><li>Novavax is available in many countries worldwide and authorized in over 43.</li><li>During 2020 and 2021, there was a lot of fear and misinformation about vaccines regarding their safety and development process.</li><li>The COVID-19 pandemic is not over yet, and people shouldn’t act as if it was.</li><li>Governments are Novavax’s primary customers.</li><li>During the pandemic, people accessed vaccines in large numbers at pharmacies, which will probably not change.</li></ul> Resources:<ul><li>Connect with and follow Silvia Taylor on <a href="https://www.linkedin.com/in/silviabtaylor/" target="_blank">LinkedIn</a>.</li><li>Follow Novavax on <a href="https://www.linkedin.com/company/novavax/" target="_blank">LinkedIn</a>.</li><li>Visit the Novavax <a href="https://www.novavax.com/" target="_blank">Website</a>!</li><li>Find out more about the COVID-19 vaccines at <a href="https://www.vaccines.gov/" target="_blank">vaccines.gov</a>.</li></ul>

S3 Ep45: Access to Information Equals Freedom of Choice—featuring Silvia Taylor

Executive Vice President, Chief Corporate Affairs and Advocacy Officer

Why Obesity Is a Chronic Disease (Not a Failure of Willpower)—featuring Isabelle

42% of adults in the US qualify as obese. But there are only a few thousand doctors board-certified in obesity, most of whom work exclusively in academic medical centers.  So, what can we do to address the obesity epidemic in our country? How do we give the 200 million Americans struggling with metabolic health access to the information and support they need? Isabelle Kenyon is Founder and CEO of <a href="https://www.joincalibrate.com/pages/hello" target="_blank">Calibrate</a>, a metabolic health company on a mission to change the way the world treats weight. In two years, Calibrate has raised more than $125 million and published clinically-reviewed results from its One-Year Metabolic Reset that exceeded the best outcomes from clinical trials across all metabolic markers. On this episode of HLTH Matters, Isabelle joins host Dr. Jessica Shepherd to explain how Calibrate partners medication and lifestyle interventions to promote long-term weight loss. Isabelle discusses the biggest contributors to sustained success with Calibrate, describing how the program helps members improve their metabolic health. Listen in for Isabelle’s insight on treating obesity like a chronic disease (not a failure of willpower) and learn how Calibrate tailors its program to your biology, your goals and your life for sustained weight loss—guaranteed. Topics Covered<ul><li>How her mom’s struggle with weight inspired Isabelle to build Calibrate</li><li>The 4 pillars of metabolic balance Calibrate uses to instill lifestyle change</li><li>How metabolic health sets us up for long-term, sustained weight loss</li><li>What it looks like to work through the Calibrate program</li><li>Why Calibrate partners medication with lifestyle interventions</li><li>How Isabelle thinks about educating consumers on metabolic health</li><li>Why Calibrate is designed to prove sustained results after medication</li><li>How engagement and community contribute to sustained success with Calibrate</li><li>How Calibrate sets expectations with clients and guarantees results</li><li>Treating obesity like the chronic disease it is vs. a failure of willpower</li></ul> Connect with Isabelle Kenyon<a href="https://www.joincalibrate.com/pages/hello" target="_blank">Calibrate</a> Connect with Dr. Jessica Shepherd<a href="https://www.hlth.com/" target="_blank">HLTH</a><a href="https://twitter.com/JShepherd_MD" target="_blank">Dr. Shepherd on Twitter</a><a href="https://www.linkedin.com/in/jessica-shepherd-md-mba-5ba9ab66/" target="_blank">Dr. Shepherd on LinkedIn</a> Resources<a href="https://www.cdc.gov/diabetes/prevention/index.html" target="_blank">National Diabetes Prevention Program</a><a href="https://www.cdc.gov/pcd/issues/2017/16_0287.htm" target="_blank">The CDC Definition of Metabolic Health</a>

S3 Ep28: Why Obesity Is a Chronic Disease (Not a Failure of Willpower)—featuring Isabelle Kenyon

Revolutionizing Drug Discovery with Machine Learning—featuring Daphne Koller

Over time, drug development has become more and more challenging. Success rates of clinical trials hover in the single digits, and the cost of developing a new treatment is greater than $2.5B. So, what can we do to make drug discovery faster, less expensive and more successful? How might advancements in machine learning and the availability of biomedical data revolutionize the drug design process? Daphne Koller is the CEO of <a href="https://insitro.com/" target="_blank">Insitro</a>, a company that is rethinking drug discovery using machine learning. She spent 18 years as a professor in the computer science department at Stanford before leaving to build the education platform <a href="https://www.coursera.org/" target="_blank">Coursera</a>. In 2016, Daphne returned to her passion for improving human health with machine learning, first as Chief Computing Officer at <a href="https://www.calicolabs.com/" target="_blank">Calico Labs</a> and then as the Founder of Insitro. On this episode of HLTH Matters, Daphne joins host Dr. Gautam Gulati to explain how her experience with her father’s autoimmune condition informs her work and why we need to rethink the fundamental categorization of disease. Daphne describes how releasing machines from our preconceptions of what’s important uncovers new science around the drivers of disease and serves as a critical starting point for developing new interventions. Listen in for Daphne’s insight on leveraging machine learning to improve clinical trials and learn why data collection should be part of the fabric of every biopharma company. Topics Covered<ul><li>Daphne’s background in machine learning, biology and medical data</li><li>How Daphne’s experience with her father’s autoimmune disease informs her work at Insitro</li><li>Why we need to rethink the fundamental categorization of what disease is</li><li>Daphne’s insight on the history of machine learning and the danger in overhyping what the technology can do</li><li>The pros and cons of using end-to-end learning to make predictions</li><li>How releasing machines from preconceptions of what’s important helps uncover new science</li><li>Why understanding the drivers of disease is a critical starting point for developing new interventions</li><li>Why data collection should be part of the fabric of every biopharma company</li><li>How Daphne’s work in machine learning can be used to improve clinical trials</li><li>Why now is the right time for a company like Insitro</li><li>How Daphne thinks about privacy and issues of informed consent </li></ul> Connect with Daphne Koller<a href="https://insitro.com/" target="_blank">Insitro</a> Connect with Dr. Gautam Gulati<a href="https://www.hlth.com/" target="_blank">HLTH</a><a href="https://www.linkedin.com/in/gautamgulati" target="_blank">Dr. G. on LinkedIn</a><a href="https://twitter.com/drgautamgulati" target="_blank">Dr. G. on Twitter</a> Resources<a href="https://www.coursera.org/" target="_blank">Coursera</a><a href="https://www.calicolabs.com/people/arthur-d-levinson" target="_blank">Art Levinson at Calico</a><a href="https://www.gsk.com/en-gb/investors/new-gsk/dr-hal-barron/" target="_blank">Dr. Hal Barron at GSK</a><a href="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information" target="_blank">Aducanumab</a><a href="https://chasingmycure.com/books/" target="_blank">Chasing My Cure: A Doctor’s Race to Turn Hope into Action by David Fajgenbaum</a><a href="https://www.gilead.com/news-and-press/press-room/press-releases/2019/4/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis" target="_blank">Insitro’s Partnership with Gilead</a><a href="https://www.ukbiobank.ac.uk/" target="_blank">UK Biobank</a> Introductory Quote[5:34] “What I really wanted to build was a company that rethought drug discovery and development from the ground up, using machine learning as a foundational tool.”

S2 Ep2: Revolutionizing Drug Discovery with Machine Learning—featuring Daphne Koller

CEO and Founder

Podcast

S1 Ep3: Partnerships + Prevention = Value-Driven Care — featuring Katie Adamson of YMCA of the USA

FEATURING